Profile
Sector:
HealthcareIndustry:
Diagnostics & ResearchCountry:
United StatesIPO:
10 August 2017Website:
http://www.dermtech.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/ADividend
Analysts recommendations
Institutional Ownership
Included in screeners
Similar companies
DMTK Latest News
SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today filed for voluntary chapter 11 protection in the U.S. Bankruptcy Court for the District of Delaware. The chapter 11 filing is a continuation of the Company's strategic alternatives review process. Currently, the Company intends to continue its laboratory operations and processing orders for the DermTech Melanoma Test (DM.
DermTech, Inc. (DMTK) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $0.93 per share a year ago.
DermTech, Inc. (NASDAQ:DMTK ) Q2 2023 Earnings Conference Call August 3, 2023 5:00 PM ET Company Participants Steve Kunszabo - Head, Investor Relations Bret Christensen - President & Chief Executive Officer Kevin Sun - Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Operator Good day, and thank you for standing by. Welcome to DermTech's Second Quarter 2023 Financial Results Call.
Nano-X is marketing a different type of X-ray system. DermTech's Smart Sticker system could change dermatology.
What type of business is DermTech?
DermTech, Inc., a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials. Further, the company develops gene expression assays for the psoriasis, atopic dermatitis, and aging of the skin to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners. It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California. On June 18, 2024, DermTech, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
What sector is DermTech in?
DermTech is in the Healthcare sector
What industry is DermTech in?
DermTech is in the Diagnostics & Research industry
What country is DermTech from?
DermTech is headquartered in United States
When did DermTech go public?
DermTech initial public offering (IPO) was on 10 August 2017
What is DermTech website?
https://www.dermtech.com
Is DermTech in the S&P 500?
No, DermTech is not included in the S&P 500 index
Is DermTech in the NASDAQ 100?
No, DermTech is not included in the NASDAQ 100 index
Is DermTech in the Dow Jones?
No, DermTech is not included in the Dow Jones index
When was DermTech the previous earnings report?
No data
When does DermTech earnings report?
Next earnings report date is not announced yet